EUVIMEDEUVIMED entdecken
Crossref

Cancer Immunotherapies Ignited by a Thorough Machine Learning‐Based Selection of Neoantigens

Sebastian Jurczak, Maksym Druchok iD

Advanced Biology · 2024

DOI: 10.1002/adbi.202400114 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Biology, 2024. Verfasst von Sebastian Jurczak und 1 weiteren Autor:innen. Beteiligte Einrichtung: SoftServe Inc., 11/13 Building B, Jaworska St., Wroclaw, 53-612, Poland. Hauptthemen laut MEDLINE: Machine Learning, Immunotherapy, Neoplasms, Antigens, Neoplasm. Die Arbeit nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identification of neoantigens, derived from somatic DNA alterations, emerges as a promising strategy for cancer immunotherapies. However, not all somatic mutations result in immunogenicity, hence, efficient tools to predict the immunogenicity of neoepitopes are needed. A pipeline is presented that provides a comprehensive solution for the identification of neoepitopes based on genomic sequencing data. The pipeline consists of a data pre‐processing step and three machine learning predictive steps. The pre‐processing step analyzes genomic data for different types of alterations, produces a list of all possible antigens, and determines the human leukocyte antigen (HLA) type and T‐cell receptor (TCR) repertoire. The first predictive step performs a classification into antigens and neoantigens, selecting neoantigens for further consideration. The next step predicts the strength of binding between neoantigens and available major histocompatibility complexes of class I (MHC‐I). The third step is engaged to predict the likelihood of inducing an immune response. Neoepitopes satisfying all three predictive stages are assumed to be potent candidates to ensure immunogenicity. The predictive pipeline is used in two regimes: selecting neoantigens from patients' sequencing data and generating novel neoantigen candidates. Two different techniques — Monte Carlo and Reinforcement Learning – are implemented to facilitate the generative regime.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Machine LearningImmunotherapyNeoplasmsAntigens, NeoplasmHumansReceptors, Antigen, T-CellHLA Antigens

Stichwörter der Autor:innen

T‐cell receptorcancer immunotherapiesmachine learningmajor histocompatibility complexneoantigens

Substanzen

Antigens, NeoplasmReceptors, Antigen, T-CellHLA Antigens

Autor:innen und Institutionen

  • SoftServe Inc., 11/13 Building B, Jaworska St., Wroclaw, 53-612, Poland.
  • SoftServe Inc., 2d Sadova St., Lviv, 79021, Ukraine.
  • Institute for Condensed Matter Physics, 1 Svientsitskii St., Lviv, 79011, Ukraine.

ORCID-Profile: Maksym Druchok

Zitieren

APA

Jurczak, S., & Druchok, M. (2024). Cancer Immunotherapies Ignited by a Thorough Machine Learning‐Based Selection of Neoantigens. Advanced Biology. https://doi.org/10.1002/adbi.202400114

Vancouver

Jurczak S, Druchok M. Cancer Immunotherapies Ignited by a Thorough Machine Learning‐Based Selection of Neoantigens. Advanced Biology. 2024. doi:10.1002/adbi.202400114

BibTeX
@article{Jurczak2024,
  author = {Jurczak, Sebastian and Druchok, Maksym},
  title = {Cancer Immunotherapies Ignited by a Thorough Machine Learning‐Based Selection of Neoantigens},
  journal = {Advanced Biology},
  year = {2024},
  doi = {10.1002/adbi.202400114}
}
Kostenlos starten →